Mamotest

What Mamotest does

Mamotest operates an AI-powered breast cancer screening and diagnostics platform headquartered in Mexico City (legal entity MAMOTEST TELEMEDICINA, S.A. DE C.V.) and operating across Argentina, Mexico, and Spain. The platform combines custom imaging systems, AI-based mammography analysis, and a digital workflow that supports patients from scheduling through screening, 24-hour diagnostic turnaround, psychological accompaniment, treatment pathway coordination, and anonymized data collection. It connects six stakeholder types — patients, medical professionals, partner clinics, pharmaceutical companies, responsible enterprises, and governments — into a single integrated workflow, and claims to be the first platform in LATAM to measure 100% patient journey traceability.

The company's revenue model spans four streams: clinical diagnostic services through its health centers and partner clinic network, enterprise health programs for corporate employee screening, government public health contracts (including with IMSS in Mexico), and pharma data services that monetize the anonymized, structured patient dataset. Patient acquisition is driven by WhatsApp-based scheduling in Argentina and Mexico, while B2B and government contracts are sold through enterprise field sales. The platform has reportedly served over 750,000 patients and engages a network of more than 3,500 health professionals, with an 87% early-diagnosis rate claimed.

The company is privately held and venture-backed, with disclosed funding of approximately $4.9 million across two rounds (2021 $1.6M led by Merck Global Health Innovation Fund; 2023 $3.3M with Johnson & Johnson Impact Ventures, Merck, Sky High, and Sonen Capital). Strategic partners include Philips Foundation, Harvard University, Johnson & Johnson, Avon, Edison Alliance, and IMSS. Recognition has come from Fast Company, World Economic Forum, Zayed Sustainability Prize, American College of Radiology, United Nations, Bloomberg, Forbes, CNN, and BBC. Leadership includes CEO Guillermo Pepe, CRO Matías Loyato, CFO Nicolás Lopérfido, CTO Germán Rodriguez, Chief Data & Patient Experience Officer Camila de Pamphilis, and Medical Director Agustín Fernandez Viña.

Name

Mamotest

Legal name

MAMOTEST TELEMEDICINA, S.A. DE C.V.

Website

https://mamotest.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Mamotest operates an AI-powered mammography and breast cancer screening platform across Argentina, Mexico, and Spain, connecting patients, clinics, radiologists, enterprises, governments, and pharma through a multi-sided workflow with 24-hour diagnostic turnaround and full patient journey traceability.

Ownership category

akta.pro rank

Product category

AI-Powered Breast Cancer Screening and Diagnostics

NAICS

Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Breast Imaging Centers (Mammography/Tomosynthesis) (HLAFAKAD)

akta.pro secondary industry

Women’s Imaging & Breast Health Centers (HLAFAJAJ)

Keywords

• AI mammography screening
• Breast cancer diagnostics
• Teleradiology platform
• Digital health screening
• Patient journey tracking

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Diagnostic Services: Revenue generated from mammography screening and diagnostic services provided through health centers operated by Mamotest
2. Enterprise Health Programs: B2B services for corporations to provide breast cancer screening to employees
3. Government Public Health Contracts: Partnerships with governments to implement breast cancer screening programs, making public health budgets more efficient
4. Pharma Data Services: Providing structured and anonymized patient data to pharmaceutical companies for clinical insights and treatment optimization

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Mamotest provides AI-powered mammography screening and breast cancer diagnostic services through a digital health platform connecting patients, clinics, radiologists, pharmaceutical companies, enterprises, and governments. The core offering combines custom imaging systems, AI diagnostic algorithms, and end-to-end patient journey tracking to deliver results within 24 hours and route patients from screening through personalized treatment.

Product overview

Mamotest is a digital health platform offering AI-powered mammography and breast cancer screening services across Latin America, Mexico, and Spain. The company provides an integrated platform consisting of AI-powered mammography analysis, customized screening programs, diagnostic services with 24-hour results, psychological support, personalized treatment pathways, and anonymized data structuring. The platform serves multiple stakeholders including patients, medical professionals, clinics, pharmaceutical companies, corporations, and governments, connecting them through a unified network that delivers end-to-end breast cancer care from screening through diagnosis to treatment. The company reports serving over 750,000 patients and achieving 87% early diagnosis rates.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-Powered Mammography Platform Central platform using artificial intelligence to analyze mammography images for breast cancer screening, providing diagnostic support and enabling early detection across a network of clinics and partner radiologists.
• Clinical Diagnostic Services Mammography screening and diagnostic services delivered through company-operated health centers (Centros de Salud), providing results within 24 hours with specialized radiologists and multidisciplinary medical network support.
• Customized Screening Program Personalized breast screening system that adapts to patient needs using a customized imaging system, transforming the mammography experience with patient support throughout the process.
• Mamotest Health Network The largest breast cancer screening network connecting clinics, radiologists, and patients through technology, enabling partner clinics to connect their mammography equipment to advanced AI-powered technology with specialized radiologists.
• Enterprise Health Programs B2B breast cancer screening programs offered to corporations for their employees, generating high community impact and supporting corporate social responsibility initiatives.
• Government Public Health Programs Partnerships with government health institutions to implement breast cancer screening programs, making public health budgets more efficient and reducing female mortality. Includes partnership with IMSS.
• Pharma Data Services Provision of structured and anonymized patient data to pharmaceutical companies for clinical insights, treatment optimization, and patient funnel analysis from screening through diagnosis.

Quantifiable outcome

• 87% of patients reach early diagnosis
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and major.

• Philips FoundationcoreStrategic or Co-development PartnerPhilips Foundation partnership for healthcare innovation and access. Philips has announced multiple healthcare access initiatives including partnerships for healthcare technology deployment in underserved communities.
• Harvard UniversitycoreStrategic or Co-development PartnerAcademic partnership for research and development in breast cancer diagnostics and healthcare technology innovation.
• Johnson & JohnsonmajorStrategic or Co-development PartnerHealthcare conglomerate partnership for breast cancer awareness and screening initiatives.
• AvonmajorGTM or Marketing PartnerPartnership for breast cancer awareness campaigns and women's health screening programs.
• Edison AlliancemajorStrategic or Co-development PartnerGlobal health technology alliance focused on digital health solutions and healthcare access.
• IMSS (Instituto Mexicano del Seguro Social)majorStrategic or Co-development PartnerMexican Social Security Institute partnership for public health screening programs.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lunit: South Korea-based AI medical imaging company whose Lunit INSIGHT MMG is one of the most widely validated AI mammography products globally. Direct competitor in AI-powered breast cancer screening and a benchmark for Mamotest's diagnostic algorithms.
• Therapixel: France-based AI mammography company with MammoScreen 2.x, FDA-cleared and CE-marked. Directly comparable as an AI-only breast imaging software vendor competing for radiologist and screening-program customers.
• DeepHealth (RadNet): RadNet-owned AI imaging unit offering Saige-Dx for mammography. Directly competes in AI breast cancer detection and benefits from RadNet's large outpatient imaging footprint, mirroring Mamotest's clinic-network model.
• Volpara Health Technologies: New Zealand-based breast imaging analytics SaaS vendor (now Lunit subsidiary) focused on density, risk, and quality metrics for mammography programs. Comparable as a software/data layer sold to breast screening programs and clinics.
• ScreenPoint Medical: Netherlands-based developer of Transpara AI for breast imaging, with FDA clearance and CE mark. Direct competitor in AI-assisted mammography reading used by hospital systems and screening programs.
• iCAD: US-based company with ProFound AI for digital breast tomosynthesis and mammography. Comparable as a dedicated AI mammography vendor selling to radiology practices and breast screening programs.
• Kheiron Medical Technologies: UK-based AI mammography vendor (Mia) focused on improving reading accuracy and workflow. Directly comparable as an AI-first breast cancer screening company selling to hospitals and public screening programs.

Broad incumbents

• Hologic: Global leader in mammography systems (3Dimensions, Genius AI) and a key infrastructure provider for breast screening programs. Mamotest connects third-party mammography equipment to its AI layer, putting it in a partner-adjacent and competitive relationship with Hologic's bundled AI offerings.

Emerging players

• Densitas: Canada-based AI vendor for breast density and screening workflow analytics. Comparable as a niche breast imaging AI software company selling to clinics and screening programs, though narrower in scope than Mamotest's full platform.

Others

• Doccla: UK-based virtual ward and remote patient monitoring provider. Comparable as a digital health platform that combines virtual care, patient monitoring, and clinical data capture, mirroring Mamotest's multi-sided telehealth-and-data model even though clinical focus differs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCyNAj9unHlrfiRnfwJV5RXA?view_as=subscriber
• Facebookfacebook.com/mamotest
• LinkedInlinkedin.com/company/mamotest
• Instagraminstagram.com/red_mamotest

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mamotest